中国泰凌医药集团有限公司（股票代码：01011）于2026年3月25日发布公告，宣布配发及发行274,751,679股代价股份。本次发行获股东特别大会于2026年1月15日批准，所涉股份于3月25日完成配发。
\n\n根据公告披露，本次发行股份数约占发行前已发行股本的40.75%，发行价格为每股0.45港元。发行完成后，公司已发行股本由674,246,015股增至948,997,694股，库藏股数量不变。
\n\n公司在公告中确认，本次股份发行已履行相关上市规则与法律法规要求，并获得董事会正式授权批准。该公告由执行董事吴铁签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.